|
 Patients given the drug, trebananib, along with a chemotherapy agent
paclitaxel, experienced overall survival of 19.3 months, compared
with 18.3 months for the placebo group.
Statistically significant improvement in overall survival was the
secondary goal of the trial.
The trial, TRINOVA-1, is the first of three late-stage studies to
evaluate safety and effectiveness of the drug in ovarian cancer
patients.
The company in 2013 reported results on the main goal of trial,
where patients survived longer without the disease getting worse
when compared with a placebo.
Jefferies analysts in a note published on Oct. 20 said oncologists
expect the drug to have little or no benefits in terms of overall
survival. "Thus, FDA approval is unlikely in our view," they wrote.
Data from the other late-stage trials are expected in the
fourth-quarter of 2014 and 2015.
The company's shares were marginally down in morning trading on the
Nasdaq.
[to top of second column] |
(Reporting by Amrutha Penumudi in Bangalore; Editing by Sriraj
Kalluvila)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
